Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. She is currently on leave.
More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero � all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

The Prescription Drug Market

By Megan McArdle
Apr 26 2010, 5:25 PM ET Comment

Commenter mbp3 has some trenchant thoughts on the pharmaceutical market:

One thing you don't mention in this post (but perhaps you discuss in your piece on pipelines) is that pharmacy benefit managers (PBMs) like Medco are structured such that their incentive to maximize profits aligns with employers/government incentive to reduce costs. Medco makes more money from each generic drug dispensed than from each brand name drug, even though the cost of brand drugs can be 10x higher.

So, I submit that the Medicare prescription drug program has come in below original spending projections because incentives are aligned: plans that prescribe more generics cost less for customers and allow the PBMs such as Medco to generate more profit. A win-win for everyone except brand drug companies.

The new HC reform bill does not have the same alignment of incentives. Goverment will attempt to cut costs administratively, by reducing Medicare payments and forcing companies to pay large fees, while doing vey little to reduce the subsidy given to employer based plans and while increasing the number and scope of mandatory coverage.

Later (s)he adds:

I think the structure of Part D had a lot to do with it. Management of the prgram was outsourced to profit maximizing companies, the reimbursement is based on a competitive bidding system so a higher bid forces a plan to charge a higher monthly premium -- which can make the plan less attractive to seniors. Also the entire program is re-bid each year -- meaning unhappy seniors can switch plans at the end of each year.

Look at the rate of generic drug substitution in Medicare - it's 70%+. Much higher than in any other country that uses a single payor / nationalized system. These systems have the same opportunity to generate savings as in the Medicare drug program, yet they have not done so, at last partly because there is little incentive to do so.

What I'm saying is, yes there were structural changes happening. BUT, the Medicare drug program was structured in such a way as to take advantgae of these changes and perhaps to accelerate them. HC reform is not.




Presented by

More at The Atlantic

Chris Matthews and Newt Gingrich: The Most Entertaining (and Reptile-Centric) Political Interview Ever Gingrich Meets Matthews: A Reptile-Centric Interview
The Right-Wing Ideologue's Guide to Obama's Teenage Pot Smoking How to Spin Obama's Teenage Pot Smoking
Have You Ever Tried to Sell a Used TV? Have You Ever Tried to Sell a Used TV?
What It Means That Computers Can Tell These Smiles Apart, But You Can't Which Smile Is Fake? (This Computer Knows)
The $630-Million Trees That Sparked a Social Media Revolt in China The $630-Million Trees That Sparked an Online Revolt

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
View All Correspondents

The Biggest Story in Photos

Where in the World? Part 3: A Google Earth Puzzle

May 25, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why You Can’t Get a Taxi

And how an upstart company may change that

Europe’s Real Crisis

The Continent’s problems are as much demographic as financial. They won’t go away soon.

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…